Ramosetron

Revision as of 22:32, 23 April 2012 by C Michael Gibson (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Ramosetron
File:Ramosetron.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Intravenous
ATC code
  • none
Pharmacokinetic data
Elimination half-life5.8 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H17N3O
Molar mass279.33 g/mol
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Ramosetron

Articles

Most recent articles on Ramosetron

Most cited articles on Ramosetron

Review articles on Ramosetron

Articles on Ramosetron in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ramosetron

Images of Ramosetron

Photos of Ramosetron

Podcasts & MP3s on Ramosetron

Videos on Ramosetron

Evidence Based Medicine

Cochrane Collaboration on Ramosetron

Bandolier on Ramosetron

TRIP on Ramosetron

Clinical Trials

Ongoing Trials on Ramosetron at Clinical Trials.gov

Trial results on Ramosetron

Clinical Trials on Ramosetron at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ramosetron

NICE Guidance on Ramosetron

NHS PRODIGY Guidance

FDA on Ramosetron

CDC on Ramosetron

Books

Books on Ramosetron

News

Ramosetron in the news

Be alerted to news on Ramosetron

News trends on Ramosetron

Commentary

Blogs on Ramosetron

Definitions

Definitions of Ramosetron

Patient Resources / Community

Patient resources on Ramosetron

Discussion groups on Ramosetron

Patient Handouts on Ramosetron

Directions to Hospitals Treating Ramosetron

Risk calculators and risk factors for Ramosetron

Healthcare Provider Resources

Symptoms of Ramosetron

Causes & Risk Factors for Ramosetron

Diagnostic studies for Ramosetron

Treatment of Ramosetron

Continuing Medical Education (CME)

CME Programs on Ramosetron

International

Ramosetron en Espanol

Ramosetron en Francais

Business

Ramosetron in the Marketplace

Patents on Ramosetron

Experimental / Informatics

List of terms related to Ramosetron

Overview

Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of “diarrhea-predominant irritable bowel syndrome in males”.[2] In India it is marketed under the brand name of "IBset".


It is only licensed for use in Japan and selected Southeast Asian countries. It is commonly sold under the tradename Nasea and in India as Nozia (300 mcg/ml Inj. & 100 mcg Tab.) [3]

References

  1. Fujii Y, Saitoh Y, Tanaka H, Toyooka H (2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342. Unknown parameter |month= ignored (help)
  2. http://www.astellas.com/en/corporate/news/detail/astellas-launches-irribow-for.html
  3. Abriged prescribing information - Nasea (MIMS Philippines). Retrieved on June 13, 2008.

Template:5-HT3 antagonists